Single-Agent Lenalidomide as Initial Induction and Postremission Therapy for Older Patients with Del(5q) Acute Myeloid Leukemia (AML)


Single-Agent Lenalidomide as Initial Induction and Postremission Therapy for Older Patients with Del(5q) Acute Myeloid Leukemia (AML)
Slides from a presentation at ASH 2010 and transcribed comments from a recent interview with B Douglas Smith, MD (1/4/11)

Sekeres MA et al. A phase II study of lenalidomide for previously untreated deletion (del) 5q acute myeloid leukemia (AML) patients age 60 or older who are not candidates for remission induction chemotherapy (Southwest Oncology Group study S0605). Proc ASH 2010;Abstract 332.

Dr Smith is Associate Professor of Oncology at The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore, Maryland.